SUNNYVALE, Calif., April 23, 2015 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that the company will
highlight new CyberKnife® and TomoTherapy®
technologies at the European Society for Therapeutic Radiology and
Oncology (ESTRO) meeting, booth #2100, in Barcelona, Spain, April
24 – 27, 2015. The CyberKnife and TomoTherapy Systems are
used to treat cancerous and benign tumors throughout the body. Each
system precisely targets the tumor, delivering the prescribed
radiation dose, while minimizing exposure to nearby healthy organs
and tissues. At ESTRO, Accuray will showcase:
- The new Delivery Analysis Software for the TomoTherapy
System: added confidence for every patient, every fraction,
through a new tool that provides unprecedented access to treatment
delivery information.
- The InCise™ Multileaf Collimator for the CyberKnife M6™
System: improves treatment efficiency for a broader range of tumor
types.
- An enhanced Synchrony® Respiratory Tracking System
for the CyberKnife System: makes it even easier for clinicians
to know they are precisely tracking and adjusting for
moving targets.
- Multiple educational opportunities: thought leaders
discuss changes in radiation therapy treatments over the last 30
years during our satellite symposium - titled "Radiation Therapy:
Connecting History, Innovation and Patients." A series of
presentations from CyberKnife and TomoTherapy users within the
Accuray Exchange in Radiation Oncology (AERO™) Academy
provides the opportunity to learn about best practices.
- Clinical evidence for both the CyberKnife and TomoTherapy
Systems: access to 100 presentations/posters is available on
the ESTRO website.
For more information please visit Accuray website.
The new Delivery Analysis Software for the TomoTherapy
System
Delivery Analysis for the TomoTherapy System recently
received 510(k) clearance from the U.S. Food and Drug
Administration (FDA), in conjunction with the CE Mark in the
European Union. The Delivery Analysis software is an innovative
tool that leverages the unique architecture of the TomoTherapy
System to provide unprecedented access to treatment delivery
information. The software provides enhanced confidence in system
performance before each treatment, and actionable insights to help
ensure all treatments stay on track. A pre-treatment test of the
multileaf collimator (MLC) checks for differences between expected
and measured MLC performance using pulse-by-pulse detector signals.
Additionally, an in-treatment analysis of each delivered fraction
is generated from exit detector data. It allows physicians to see
if a particular fraction was not delivered as expected and helps to
clarify the nature of the issue that led to the dose miss
observed.
An enhanced Synchrony® Respiratory Tracking System for the
CyberKnife System
The Synchrony System is the only
clinically proven system that uses continual image guidance to
automatically adjust the movement of the beam in synchronization
with movement of the target volume. This new technology enables
clinicians to:
- Improve their ability to track moving targets and minimize
treatment margins.
- Confidently set up Synchrony Respiratory Tracking with just a
few mouse clicks.
- Set up and treat moving targets, in particular lung cases,
faster and more easily.
Satellite Symposium: "Radiation Therapy: Connecting History,
Innovation and Patients"
The symposium will be held on
Saturday, 25 April 2015 from 13:15 to
14:30, room 111 (level 1). Presentations will explore the progress
that has been made over the last 30 years in radiation therapy and
discuss Accuray's contribution to setting the standard for the
precise treatments that are used today and will be used in the
future. Chaired by Prof. Jurgen Peter
Debus, M.D., Ph.D., Managing Director of the Department of
Radiation Oncology, Heidelberg University Hospital, Heidelberg,
Germany, Symposium speakers will
include: Dr. Cary Adams, CEO, the
Union for International Cancer Control (UICC) and Chair of the NCD
Alliance in Geneva, Switzerland;
Prof. Ben J.M. Heijmen, Ph.D., Head
of the Section of Medical Physics, Department of Radiation
Oncology, Erasmus Medical Center, Rotterdam, The Netherlands; and Prof.
Thomas Rockwell Mackie, Ph.D.,
Emeritus Professor, Departments of Medical Physics and Human
Oncology, University of Wisconsin School of
Medicine and Public Health, Madison, USA.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a
radiation oncology company that develops, manufactures and sells
precise, innovative tumor treatment solutions that set the standard
of care with the aim of helping patients live longer, better lives.
The company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press
release that are not statements of historical fact are
forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are
not limited, to clinical applications, clinical results, patient
outcomes and Accuray's leadership position in and future
contributions to radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed under
the heading "Risk Factors" in the company's report on Form 10-K,
filed on August 29, 2014, the
company's reports on Form 10-Q, filed on November 7, 2014 and February 6, 2015, and the company's other filings
with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/accuray-to-showcase-new-cyberknife-and-tomotherapy-technologies-at-estro-2015-300070822.html
SOURCE Accuray